

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
18 January 2024 (18.01.2024)



(10) International Publication Number  
**WO 2024/015717 A2**

(51) International Patent Classification:  
*A61K 31/517* (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:  
PCT/US2023/069826

(22) International Filing Date:  
07 July 2023 (07.07.2023)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:  
63/359,835 09 July 2022 (09.07.2022) US  
63/359,875 10 July 2022 (10.07.2022) US  
63/416,453 14 October 2022 (14.10.2022) US  
63/440,406 21 January 2023 (21.01.2023) US  
63/463,006 29 April 2023 (29.04.2023) US

(71) Applicant: **PLIANT THERAPEUTICS, INC.** [US/US];  
260 Littlefield Avenue, South San Francisco, California  
94080 (US).

(72) Inventors; and  
(71) Applicants: **LEFEBVRE, Eric** [CA/US]; c/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South San Francisco, California 94080 (US). **COSGROVE, Gregory P.** [US/US]; c/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South San Francisco, California 94080 (US). **TURNER, Scott** [US/US]; c/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South San Francisco, California 94080 (US). **DECARIS, Martin L.** [US/US]; c/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South San Francisco, California 94080 (US). **SCHAUB, Johanna Roberta** [US/US]; c/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South San Francisco, California 94080 (US).

(54) Title: INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS



**FIG. 31**

(57) Abstract: The invention relates to methods of (i) treating a subject for a disease, (ii) amelioration of decline of forced vital capacity in a subject in need thereof, (iii) modulating  $\alpha\beta_6$  integrin,  $\alpha\beta_1$  integrin, or both  $\alpha\beta_6$  integrin and  $\alpha\beta_1$  integrin in a subject in need thereof, (iv) increasing the expression of one or more genes in a subject in need thereof, (v) decreasing the expression of one or more genes in a subject in need thereof, and (vi) modulating the activity of at least one gene affecting fibrotic activity in a subject in need thereof, comprising administration of compounds of Formula (A), Formula (I), Formula (II), or (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthylidin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, or a pharmaceutically acceptable salt thereof as described herein; and administering to the subject at least a second drug

[Continued on next page]

(74) **Agent: CERPA, Robert et al.;** Morrison & Foerster LLP,  
755 Page Mill Road, Palo Alto, California 94304-1018  
(US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

selected from pirfenidone and nintedanib, or a salt thereof. The compounds and pharmaceutical compositions thereof are  $\alpha\text{v}\beta_6$  integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).